Pfizer Inc

PFENYSE · USD
28.67USD0.00 (+0.92%)
879

Pfizer Inc (PFE) Wheel Strategy

PFE wheel strategy scan found 118 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 49.4%.

Read more

Running a PFE wheel strategy lets you generate consistent premium income on Pfizer Inc while setting your own entry and exit prices on the underlying. Pfizer Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own PFE, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best PFE wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on PFE, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable PFE wheel from a losing one.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.

In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the PFE wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your PFE wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Oct 2, 202628.50$0.25$0.27-0.41742%57.6%49.4%455
Oct 9, 202628.50$0.36$0.39-0.421442%55.6%35.2%92
Nov 6, 202628.50$0.89$1.11-0.444242%53.7%33.8%0
Oct 16, 202628.50$0.46$0.50-0.432142%54.7%30.5%523
Oct 23, 202628.50$0.47$0.64-0.432842%54.2%29.3%50
Nov 6, 202628.00$0.62$0.81-0.374242%62.3%25.1%4
Oct 30, 202628.50$0.55$0.66-0.433542%53.9%24.2%91
Oct 2, 202628.00$0.10$0.12-0.22742%77.2%21.4%1,013
Nov 20, 202628.00$0.84$0.88-0.375642%60.9%20.5%6,397
Oct 9, 202628.00$0.19$0.21-0.271442%70.1%19.6%183

As of September 25, 2026

Run the Wheel on PFE With Confidence

Find the best PFE wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial